A RANDOMIZED PROSPECTIVE STUDY COMPARING THE EFFECTIVENESS OF MITOMYCIN C AND MITOMYCIN/S2 COMPLEX SEQUENTIAL INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER

Abstract

Objective: Comparison of two protocols regarding efficacy and toxicity of intravesical mitomycin C versus mitomycin C and S2 complex sequential therapy for superficial transitional carcinoma of urinary bladder. Methods: A prospective, randomized parallel two lines of treatment groups. Seventy-three patients were evaluated after transurethral resection of superficial bladder cancer with median follow-up of 26 months. In group A, 37 patients received intravesical mitomycin C 30mg on day1 weekly for 6 weak and monthly for 12 month, while group B (36 patient) received in addition to mitomycin C, intravesical S2 complex 3ml on day 2. Statistical analysis performed by Kaplan-Meier methods. Result: After follow-up of 26 months, 46% of patient given mitomycin C were disease free compared to 70% for that of group B patient who received mitomycin C and S2 complex, with no significant difference in incidence of the adverse effects. Conclusion: The results show that intensive intravesical instillation of sequential mitomycin C and S2 complex; were highly effective in eradication and/or prophylaxis of superficial transitional bladder cancer.Key ward: Transurethral resection; bacillus Calmitte-Guerin; complete response; mitomycin C, carcinoma in situ